c ebpβ-lip drug Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer | Journal of Experimental & Clinical Cancer Research C/EBPβ sustains the oncogenic program
C EBP sustains the oncogenic program of AML cells by cooperating with MYB and co activator p300 in a transcriptional module Experimental Hematology C EBP LIP induces cancer type metabolic reprogramming by regulating the let 7 LIN28B circuit in mice Communications Biology Frontiers C EBP as a master regulator of inflammasome signaling in neurodegenerative diseases: mechanisms and therapeutic implications C EBP beta (LAP) Antibody Cell Signaling Technology
Pay in 4 interest-free payments of $6.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16


